Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $48.40.

Several brokerages recently issued reports on AAPG. Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Piper Sandler initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. BTIG Research initiated coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a report on Monday, November 24th.

Ascentage Pharma Group International Stock Performance

AAPG opened at $22.25 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The stock has a fifty day simple moving average of $25.45 and a two-hundred day simple moving average of $32.19. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth approximately $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the third quarter worth approximately $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Finally, UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.